A
Alcista
Alcista · 25%NAUT
$0.84
Precio del escenario
$2.630
+0.728 (+27.67%)Al cierre
Loading chart…
- Máximo
- 2.680
- Apertura
- 2.030
- Precio medio ponderado por volumen
- 2.43
- Volumen
- 14.97M
- Capitalización
- 285.60M
- Mínimo
- 1.970
- Importe
- 36.33M
- EV/EBITDA, TTM
- -0.66
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprises the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs. Its platform consists of integrated reagents, fluidics, imaging, and ultra-dense nano-array flow cells.
Análisis de IA of Nautilus Biotechnology Inc (NAUT)
ComprarNautilus Biotechnology is a good buy right now due to its recent analyst upgrades and potential for significant price appreciation. The current price is $2.06, with a consensus price target of $4.08, indicating a potential upside of over 100%. Additionally, the company has shown a gross margin of 92.11%, which is exceptionally strong for a biotech firm. However, the main risk is its negative net income margin of -7615.26%, which highlights ongoing financial challenges.
Métricas de valoración
El PER previsto actual de Nautilus Biotechnology Inc (NAUT) es 0.00, frente a su media de 5 años de -3.86.
Escenarios de precio de Alphio AI para NAUT
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con NAUT en cartera
Cronología de eventos
Noticias
6.009-30NASDAQ.COMRoth Capital Initiates Buy Rating on Nautilus Biotechnology
6.009-29CNBCLatest Wall Street Rating Updates
3.509-04NewsfilterNautilus Biotechnology Unveils New Research Findings on Tau Proteoforms
9.507-29NASDAQ.COMNautilus Biotechnology Reports Q2 Financial Results with First Revenue Generation
9.507-28seekingalphaNautilus Biotechnology Q2 2026 Earnings Call Insights
Preguntas frecuentes sobre NAUT, respondidas por Alphio AI
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprises the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs. Its platform consists of integrated reagents, fluidics, imaging, and ultra-dense nano-array flow cells. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Nautilus Biotechnology is a good buy right now due to its recent analyst upgrades and potential for significant price appreciation. The current price is $2.06, with a consensus price target of $4.08, indicating a potential upside of over 100%. Additionally, the company has shown a gross margin of 92.11%, which is exceptionally strong for a biotech firm. However, the main risk is its negative net income margin of -7615.26%, which highlights ongoing financial challenges.
Comunidad
Más ↗
$NAUT had several bids between $1.00-1.35, but this was the only one that filled. Might have to consider looking for a higher low now.
Mostrar más
$NAUT (Nautilus Biotechnology) is breaking out of a multi-week base on the daily chart: • Structural Intersection: After the decline from the $3.20–$3.40 region, price compressed inside a tight $0.84–$1.05 box. Wednesday's surge through $1.05, on expanding volume, is the first clean resolution of that range to the upside. • Key Support Zone: The $0.92–$0.98 area (prior range high turned support) is the demand floor. A sustained hold above $1.00 keeps the breakout structure intact. • Asymmetric Projection: With risk defined against the $0.84 base, a hold above $1.12 opens a measured path toward the $1.70–$1.80 zone (~+61%). Small-cap biotech coming out of a washed-out range. Breakout only counts if the box holds as support. NFA / DYOR
Mostrar más
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.